Biotech Research Typewriter Therapeutics Raises $56M in Series A Funding
Sep 3, 2026 | By Devin Jacobs
SUMMARY
- Typewriter Therapeutics raised $56M in Series A funding.
- The funding will support R&D and operations.
- Typewriter Therapeutics develops RNA-based gene therapies.
Follow us
Follow usTypewriter Therapeutics, a Cambridge, MA-based provider of a gene writing technology platform for genetic medicines, has raised $56 million in a Series A financing round led by AN Venture Partners and RA Capital Management.
The round also saw participation from ANRI, Gemseki, and SBI US Gateway Fund.
The company will use the capital to expand operations and research and development.
Funding Snapshot
| Metric | Details |
|---|---|
| Fundraise Amount | $56 Million |
| Valuation | Not disclosed |
| Company | Typewriter Therapeutics |
| Sector | Biotechnology / Gene Therapy |
| Headquarters | Cambridge, Massachusetts, US |
RECOMMENDED FOR YOU
[Funding alert] CA-based CLARA Analytics Secures an Investment from Nationwide Ventures
Devin Jacobs
Feb 22, 2024
About Typewriter Therapeutics
Founded in 2022, Typewriter Therapeutics develops RNA-based gene therapies for cancer, autoimmune diseases, and severe genetic disorders. The company’s technology is designed to enable targeted insertion of complete therapeutic genes, potentially creating durable and re-dosable treatments.
Read More:Fintech Startup TabaPay Raises $155M in Funding
Core offerings include:
- RNA-based gene therapies
- Targeted gene insertion
- TPRT gene writing platform
- Genetic medicine development
Core Technologies / Products / Services
| Capability/Product | Application/Use Case |
|---|---|
| TPRT Technology | Enables targeted insertion of therapeutic genes |
| R2 Retrotransposon | Serves as the natural gene-insertion mechanism |
| All-RNA Therapy | Delivers the components needed for gene insertion |
| Gene Writing Platform | Supports development of durable genetic medicines |
Leadership Comments
"By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches," said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics.
"The mRNA vaccines proved to the world that RNA delivered by a lipid nanoparticle can become a medicine at global scale. Typewriter takes that breakthrough a decisive step further –using only RNA not to express a transient protein, but to write a durable therapeutic gene into a precise, safe location in the genome, without a virus," said Mikael Dolsten, MD, PhD, independent board director at Typewriter Therapeutics and former Chief Scientific Officer and President of Worldwide Research & Development at Pfizer.
Readc More:Boston-Based Elucid Raises $55M in Series D Funding
Recommended Stories for You
Devin Jacobs Jul 15, 2026
Devin Jacobs Feb 8, 2024
Devin Jacobs Feb 14, 2024
Team SR Aug 27, 2024
Devin Jacobs Jul 9, 2026
Trending Stories
Drink mix brand FAVE Scores $1M in Seed Funding led by Supernatural Ventures
Cybersecurity Startup Beacon Security Scores $13M in Seed Funding
[Funding alert] NYC-based Qortex Secures $10m in Funding
AI Startup Smallest.ai Scores $13M in Series A Funding
Fintech Startup Glacis Labs Lands $6.8M to Expand Digital Asset Clearing Platform
California-Based Coverwatch Bags $4.5M in Pre-Seed Funding
Climate-Tech Startup Kind Designs Raises $10M in Pre-Series A Funding
Vermont-Based The Farmer Companies Scores $17M in Series A Funding
